Plus Therapeutics Inc (PSTV) Stock Analysis
Verdict: AVOID
PSTV is a high-burn clinical lottery where clinical efficacy in CNS cancers must outrun a cash runway expiring in less than six months.
Investment score: 38/100
Analysis as of
Is Plus Therapeutics Inc stock worth reviewing? The TradeMates thesis
Plus Therapeutics is a speculative micro-cap biotech facing a severe cash crunch. While its radiotherapy platform has high theoretical value, its financial trajectory points toward significant shareholder dilution before any commercial milestone is reached.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Plus Therapeutics Inc opportunities and risks
What speaks for PSTV
- Radiotherapy Platform Validation
What speaks against PSTV
- Imminent Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PSTV | n/a | 2.5x | n/a | 92.8% | -230.2% | -170.7% |
| LTRN | n/a | 0.0x | n/a | 0.0% | 0.0% | -29.3% |
| ATYR | n/a | 231.5x | n/a | -11754.7% | -36857.4% | -134.8% |
| ELUT | 0.8x | 2.6x | n/a | 54.0% | 312.1% | -110.1% |
| RNXT | n/a | 21.5x | n/a | 78.7% | -824.0% | -35.3% |
| GRML | n/a | 0.0x | n/a | 0.0% | 0.0% | -27.2% |
| Peer median | n/a | 2.6x | n/a | 0.0% | 0.0% | -35.3% |
Frequently asked questions about Plus Therapeutics Inc (PSTV)
Is PSTV stock a good investment?
The TradeMates model rates Plus Therapeutics Inc as AVOID with an investment score of 38/100. Plus Therapeutics is a speculative micro-cap biotech facing a severe cash crunch. While its radiotherapy platform has high theoretical value, its financial trajectory points toward significant shareholder dilution before any commercial milestone is reached. This is algorithmic model output, not personal investment advice.
Is PSTV stock a buy?
The TradeMates model verdict for PSTV is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.